Company Filing History:
1 out of 52 
1 out of 4,455 
Years Active: 2015
Title: **Jerome Thomas Mettetal, II: Innovator in Antibody Technology**
Introduction
Jerome Thomas Mettetal, II is a prominent inventor located in Cambridge, MA, who has made significant contributions to the field of biochemistry, particularly in the development of antibodies with unique binding properties. His innovative work has resulted in a patent that addresses the challenges associated with antigen binding and clearance in therapeutic applications.
Latest Patents
Mettetal holds a patent for "Anti-PCSK9 antibodies with pH dependent antigen binding." This invention focuses on antibodies that exhibit pH-dependent binding characteristics, enabling them to have higher affinity for their antigen at physiological pH compared to lower pH environments. This unique property allows for increased antibody half-life and enhanced therapeutic efficacy, particularly in the context of antigens that are cleared through antigen-mediated processes.
Career Highlights
Throughout his career, Mettetal has been affiliated with reputable organizations, including Rinat Neuroscience Corporation and Pfizer Corporation. His work at these companies has allowed him to advance research in antibody technology, contributing to improvements in drug design and therapeutic strategies targeting PCSK9 and other antigens.
Collaborations
Jerome has collaborated with esteemed professionals in his field, including Jaume Pons and Jeffrey Raymond Chabot. These collaborations underline the importance of teamwork in driving innovation and developing breakthrough technologies in biotechnology.
Conclusion
Jerome Thomas Mettetal, II's contributions to the field of antibody research exemplify the impact of innovative thinking on medical advancements. His patent addressing pH-dependent antigen binding is a testament to his expertise and commitment to improving therapeutic outcomes in patients. As the field of biochemistry and pharmaceuticals continues to grow, Mettetal’s work will undoubtedly be influential in shaping the future of antibody-based therapies.